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a-Melanocyte stimulating hormone (a-MSH) is known to have pleiotrophic functions including pigmentary, anti-inflammatory,
antipyretic and immunoregulatory roles in the mammalian body. It is also reported to influence melanoma invasion with levels of a-,
b- and g-MSH correlated clinically with malignant melanoma development, but other studies suggest a-MSH acts to retard invasion. In
the present study, we investigated the action of a-MSH on three human melanoma cell lines (HBL, A375-SM and C8161) differing in
metastatic potential. a-melanocyte-simulating hormone reduced invasion through fibronectin and also through a human
reconstructed skin composite model for the HBL line, and inhibited proinflammatory cytokine-stimulated activation of the NF-kB
transcription factor. However, A375-SM and C8161 cells did not respond to a-MSH. Immunofluorescent microscopy and Western
blotting identified melanocortin-1 receptor (MC-1R) expression for all three lines and MC-2R on HBL and A375-SM lines. Receptor
binding identified a similar affinity for a-MSH for all three lines with the highest number of binding sites on HBL cells. Only the HBL
melanoma line demonstrated a detectable cyclic adenosine monophosphate (cAMP) response to a-MSH, although all three lines
responded to acute a-MSH addition (þ ()-N6-(2-phenylisopropyl)-adenosine (PIA)) with an elevation in intracellular calcium. The
nonresponsive lines displayed MC-1R polymorphisms (C8161, Arg (wt) 151/Cys 151; A375-SM, homozygous Cys 151), whereas the
HBL line was wild type. Stable transfection of the C8161 line with wild-type MC-1R produced cells whose invasion was significantly
inhibited by a-MSH. From this data, we conclude that a-MSH can reduce melanoma cell invasion and protect cells against
proinflammatory cytokine attack in cells with the wild-type receptor (HBL).
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The aim of this study was to investigate how a-melanocyte-
simulating hormone (a-MSH) affects melanoma cell invasion and
resistance to proinflammatory cytokines. a-melanocyte-simulating
hormone arises from the proteolytic cleavage of pro-opiomelano-
cortin (POMC) and is responsible for pigmentation in lower
vertebrates (Eberle 1988). POMC and a-MSH are synthesised by
normal human keratinocytes and melanocytes (Schauer et al, 1994;
Kippenberger et al, 1995; Chakraborty et al, 1996), and adminis-
tration in vivo can produce skin darkening in humans (Lerner and
McGuire 1961). Although cultured mouse melanocytes and
melanoma cells reliably pigment to a-MSH addition (Eberle,
1988), human melanocytes have little or no response (Friedmann
et al, 1990; De Luca et al, 1993; Hedley et al, 1998a). Responses
relate to skin type (Hunt et al, 1994) with melanocytes from type 1
and type 2 skin donors rarely pigmenting to a-MSH in vitro,
whether in 2-D (Hedley et al, 1998a) or 3-D culture (Hedley et al,
2002).
a-Melanocyte-simulating hormone also has potent antipyretic
and anti-inflammatory responses, inhibiting acute and chronic
inflammation in a number of tissues (Lipton and Catania, 1997),
including for example ultraviolet (UV) irradiation (Luger et al,
1999). Our group has showed that a-MSH can inhibit tumour
necrosis factor-a (TNF-a)-induced upregulation of intercellular
adhesion molecule-1 (ICAM-1) in human melanocytes and
melanoma cells (Hedley et al, 1998b; Morandini et al, 1998) and
reduce interactions between cytokine-stimulated melanoma cells
and T lymphocytes (Hedley et al, 2000). The expression of
inflammatory cytokines and adhesion receptors such as ICAM-1
are largely under the control of the transcription factor NF-kB
(Ghosh et al, 1998). We also found a-MSH to reduce TNF-a-
stimulated NF-kB activity (and oxidative stress) in keratinocyte
and melanoma lines (Haycock et al, 1999, 2000), suggesting
protection of the epidermis from inflammatory and oxidative
stresses. In addition, B16 melanoma cells respond to a-MSH with
inhibition of growth and reduced adhesion (Robinson and Healy,
2002).
Melanocortin (MC) action arises via G-protein receptor signal-
ling. Five receptors (MC-1R– MC-5R) have been cloned to date
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(Mountjoy et al, 1992) and MC-1R is expressed on human
keratinocytes, melanocytes and melanoma cells (Donatien et al,
1992; De Luca et al, 1993; Bohm et al, 1999). Loss-of-function
polymorphic variants exist (Valverde et al, 1995) and are
associated with red-haired individuals who pigment poorly
(Schio¨th et al, 1999). Reports also suggest that MC-1R polymorph-
isms correlate with cutaneous melanoma (Box et al, 1997; Jime´nez-
Cervantes et al, 2001), although not all studies have confirmed this
(Ichii-Jones et al, 1998).
Melanoma patients show high levels of a-MSH in plasma and
tumours (Ghanem et al, 1989a, b), thought to correlate with
malignant melanoma development (Liu and Johansson, 1995).
However, a-MSH is reported to both stimulate and inhibit
melanoma invasion in vitro and in vivo. Murine melanoma cells
respond to a-MSH stimulation in vitro with a higher number
of metastases in vivo, and a positive correlation exists between
murine melanoma cell response to a-MSH (assessed by cAMP
elevation) in vitro and metastatic success in vivo (Sheppard
et al, 1984; Hill et al, 1990). However, a-MSH can inhibit
B16-BL6 melanoma invasion through reconstituted (Matrigel)
basement membrane (Murata et al, 1997), and reduce colony
formation by 50%, in agreement with similar work in B16-F10 cells
(Kameyama et al, 1990). Thus, it is unclear if a-MSH promotes or
inhibits melanoma invasion, or if it is the immune response to
melanoma.
As the role of a-MSH in melanoma progression is unclear, and
in light of additional cytoprotective roles, the aim of this study was
to investigate the actions of a-MSH on both melanoma cell
invasion and the ability of a-MSH to attenuate the response of cells
to proinflammatory cytokines using human melanoma lines.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle’s medium (DMEM), glutamine, peni-
cillin, streptomycin, amphotericin B, vitamin concentrate, Triton X
100, newborn calf serum (NBCS), Ham’s F10 and F12, nonessential
amino acids (NEA) and trypsin/EDTA were from Gibco BRL,
Paisley, UK. Dispase was from Difco Laboratories, Detroit, USA.
Fetal calf serum (FCS) was from GlobePharm Ltd, Esher, UK.
Phosphate-buffered saline (PBS) was from Oxoid Ltd, Basingstoke,
UK. Transwellt plates (24-well) were from Corning Costar
Corporation, Cambridge, MA, USA. Collagenase A and TNF-a
were from Boehringer Mannheim, Lewes, UK. Tri-iodothyramine,
epidermal growth factor (EGF), hydrocortisone, adenine, insulin,
transferrin, isobutyl methylxanthine (IBMX), MTT, N-(A-Rham-
nopyranosyloxyhydroxy-phosphinyl)-leu-trp sodium (Phosphora-
midon), RPMI-1640, sodium pyruvate, D-glucose, bovine serum
albumin (BSA), Cell Dissociation Solution, human plasma
fibronectin, ()-N6-(2-phenylisopropyl)-adenosine (PIA) and try-
pan blue were from Sigma Chemicals Ltd, Poole, UK. Paraformal-
dehyde, NH4Cl, glycerol, circular glass coverslips and poly-L-
lysine-coated microscope slides were from BDH, Poole, UK. a-
Melanocyte-simulating hormone was from Bachem, Essex, UK.
Primary goat polyclonal IgG-specific antibody to MC-1R (N-19)
and MC-2R (C-16), and anti-NF-kB (p65) goat polyclonal IgG were
from Santa Cruz Biotechnology Inc., CA, USA. Biotinylated anti-
goat IgG and Streptavidin-FITC were from Vector Laboratories,
Burlingame, USA. Fura-2-AM was from CN Biosciences, Beeston,
UK. Prolong Antifade coverslip mounting medium was from
Molecular Probes, Leiden, the Netherlands. Murine anti-HMB45
IgM was from Dako, Carpintera, USA. Bicinchoninic acid (BCA)
assay kit was from Pierce (Tattenhall, Cheshire, UK). Enhanced
chemiluminescence (ECL) kit was from AmershamPharmacia
(Amersham, UK). Wizard kit and TfXt-50 Reagent were from
Promega (Southampton, UK). pRc/CMV and geneticin (G-418)
were from Invitrogen (Groningen, The Netherlands). All chemicals
were of analytical grade unless otherwise indicated.
METHODS
Keratinocyte cell culture
Normal human skin keratinocytes were isolated as detailed
previously (Chakrabarty et al, 1999; Eves et al, 2000). Freshly
isolated cell suspensions were seeded onto dermal composites at
1 106 viable cells within a 1 cm2 stainless steel ring (see the
section ‘Reconstructed skin model of invasion’ below for further
details).
Human fibroblast cell culture
Dermal layers obtained after keratinocyte isolation were then used
to isolate human skin fibroblasts (detailed in Chakrabarty et al,
(1999); Eves et al, 2000). Fibroblast cells (passage 3 –passage 9)
were seeded onto dermal composites at 1 105 cells per composite
ring (see the section ‘Reconstructed skin model of invasion’ below
for further details).
Human melanoma cell line culture
Three human cutaneous melanoma cell lines were used: (i) HBL;
(ii) A375-SM and (iii) C8161. HBL is derived from a lymph node
metastasis of a nodular melanoma established in one of our
laboratories (Ghanem et al, 1988). Cells were maintained as
detailed in Eves et al (2000) and passaging was in 0.02% EDTA. For
composite experiments, HBLs were resuspended in keratinocyte
culture medium (KCM); for invasion, attachment and proliferation
assays, HBL cells were resuspended in serum-free invasion assay
medium (SFIAM). For MC-1R and NF-kB immunolabelling, and
calcium and cyclic adenosine monophosphate (cAMP) experi-
ments, HBLs were resuspended in Ham’s F10 melanoma culture
medium (HMCM). The A375-SM cell line was a generous gift from
Professor IJ Fidler (USA) via Professor MJ Humphries (University
of Manchester, UK). A375 was established in culture from a lymph
node metastasis of a 54-year-old female (Giard et al, 1973). These
cells are heterogeneous in nature and a highly metastatic variant
(A375-SM) was established in culture from lung metastases
produced by parental A375 cells growing subcutaneously in nude
mice (Kozlowski et al, 1984). The C8161 melanoma line was kindly
donated by Professor F Meyskens (University of California, Irvine,
USA) via Professor M Edwards (University of Glasgow, UK). C8161
was established from an abdominal wall metastasis (Bregman and
Meyskens, 1983). Both A375-SM and C8161 cells (and B16 F10C1
murine melanoma cells used as a positive control for measurement
of cAMP) were cultured in Eagle’s modified essential medium
(EMEM) supplemented with 10% (v v1) FCS, 2 mM L-glutamine,
100 IU ml1 penicillin and 100 mg ml1 streptomycin, 1.2 mg ml1
amphotericin B, 1.5% (v v1) (100 stock) vitamin concentrate,
1 103 mol l1 sodium pyruvate, 1% (v v1) NEA and 0.187% (v v1)
sodium hydrogen carbonate, and incubated at 371C in humidified
5% carbon dioxide/95% air. When approximately 80– 90%
confluent, cells were passaged using Cell Dissociation Solution.
For invasion, attachment and proliferation assays, A375-SM and
C8161 melanoma cells were resuspended in SFIAM, and for MC-1
receptor and NF-kB immunolabelling and calcium and cAMP
experiments, cells were resuspended in complete EMEM.
Generation of a melanoma cell line with stable expression
of MC-1 receptor
A stable C8161 melanoma cell line expressing functional MC-1
receptors was isolated by transfecting C8161 cells with vector pRc/
CMV carrying MC-1 cDNA (kindly donated by Professor JES
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Wikberg, Uppsala University, Sweden). Briefly, cells were plated in
100 mm dishes in complete EMEM media. After growth to
approximately 70% confluence, the cells were transfected with
15mg of pRC/CMV/MC-1 DNA using Tfxt-50 Reagent, according
to the manufacturer’s (Promega) protocol. Individual transfectants
were isolated and cloned by limiting dilution following growth in
complete EMEM media containing 500mg ml1 geneticin (G-418).
Indirect immunofluorescent labelling of MC-1R and
NFjB/p65
C8161 (5 103 cells ml1) and A375-SM (1 104 cells ml1) cells
were resuspended in EMEM, and HBL (3 104 cells ml1) were
resuspended in HMCM and seeded onto sterile circular glass
coverslips (13 mm diameter) in 24-well plates and incubated at
371C in humidified 5% carbon dioxide/95% air until approxi-
mately 80–90% confluent. For the NFkB/p65 studies, melanoma
cells were incubated in the appropriate medium (HMCM/
EMEM)7a-MSH (1012106 M) for 15 min, followed by a 1 h
incubation in fresh medium7TNF-a (300 U ml1). Cells were
immunofluorescently labelled for MC-1R and NFkB/p65 as
detailed previously (Moustafa et al, 2002). Melanocortin-1
receptors and NFkB/p65 in each melanoma were visualised using
epifluorescent illumination (FITC filter, lex¼ 490 nm,
lem¼ 523 nm), and nuclei were visualised using a rhodamine filter
(lex¼ 555 nm, lem¼ 580 nm) with a Nikon X600 microscope.
Digital images of MC-1R/NFkB/p65 and nuclei were captured and
overlaid using Adobe Photoshop. Cellular movement of NF-kB/p65
was evaluated as described previously (Moustafa et al, 2002).
Western blotting for MC-1R and MC-2R
Melanoma cells were seeded into six-well plates at 105 cells per well
and grown until 60% confluent. Western blot analysis was carried
out as detailed previously (Moustafa et al, 2002). Immunoreactive
bands were visualized using an ECL kit.
MSH receptor binding studies
Saturation and competitive binding assays were performed using
the following modification of a previously published method
(Ghanem et al, 1988). Saturation assays allowed calculation of total
receptor numbers and competitive binding allowed calculation of
the affinity of the receptors for the peptide. Briefly,
250 103 d.p.m. of 125I-[Nle4, Dphe7]-a-MSH in 100 ml was added
to 106 cells (100ml) previously mixed with [Nle4, Dphe7]-a-MSH
(concentration ranging from 1012 to 106 M) in PBS pH 7.2
containing 0.1% BSA, 6.25 mM Hepes and 0.1% trasylol. After
mixing, the tubes were incubated at 371C for 45 min before cell
separation by repeated centrifugation and washing. The pellet-
associated radioactivity was then measured in a gamma counter.
DNA extraction, amplification and sequencing of MC-1R
Briefly, genomic DNA was extracted from the HBL, C8161 and
A375-SM cell lines using a Wizard kit. The full-length coding
sequence of the MC-1R gene was amplified using primers as
detailed previously (Jime´nez-Cervantes et al, 2001).
Measurement of intracellular free calcium
Cells were grown as monolayers on glass coverslips until nearly
confluent and incubated with 4 mM Fura-2 AM for 15 min at 371C.
Cells were then washed with balanced salt solution (1.5 mM calcium
chloride, 0.5 mM magnesium chloride, 135 mM sodium chloride,
4.5 mM potassium chloride, 5.6 mM glucose, 10 mM Hepes, pH 7.4),
and coverslips of cells were examined in a fluorimeter (Kontron
SKM 25) to determine changes in intracellular calcium in response
to the adenosine agonist PIA (10mM), and a-MSH (1012 M to
106 M) alone or in combination. Details are as previously
described in Metcalfe et al (1998).
Measurement of cAMP
Both intracellular and extracellular cAMP responses to peptide
addition were examined. For intracellular cAMP, cells were
prelabelled with tritiated adenosine for 2 h. Cells were then
preincubated with 0.8 mM IBMX for 15 min prior to addition of
a-MSH at a range of concentrations for 10 min. Cells were washed
with PBS, 100 ml ethanol was added and the cells were stored at
201C. Assay details are as previously described (Metcalfe et al,
1998). Extracellular cAMP in the media was determined using a
commercially available kit (Biomedical Technologies Inc., USA), in
which cAMP measurement is based on competitive binding
between cAMP and an alkaline phosphate derivative of cAMP for
a limited amount of specific antibody. A secondary antibody
separates the bound cAMP from the free cAMP. A coloured end
product is determined using a microtitre plate reader, measuring
absorbance at 405–410 nm. Results shown are of three separate
experiments.
Fibronectin invasion assay
Transwellt inserts were coated with a layer of human fibronectin
as described previously (Dewhurst et al, 1997), and placed onto a
24-well tissue culture plate containing 600ml SFIAM (RPMI-1640
medium supplemented with 20 ng ml1 EGF, 0.2% (w v1) D-
glucose solution and 0.1% (w v1) BSA). Cell suspensions (50 ml
containing 0.6 105 A375-SM cells or 1.2 105 HBL/C8161 cells in
SFIAM) plus an equivalent volume of SFIAM (7pharmacological
agent) were added to each insert and cells were incubated for 15–
52 h at 371C in 5% CO2/95% air. As cell lines invaded at different
rates, HBL cells were cultured for 20 h (Dewhurst et al, 1997;
Richardson et al, 1999), C8161 cells for 15 h and A375-SM cells for
52 h, to obtain comparable levels of invasion. For the 52 h
incubation time, a cell density of 0.6 105 cells was used. After
incubation, medium (containing cells) was collected from the
upper and lower compartments of the Transwellt chamber and
placed into preweighed LP4 perspex tubes. The medium removed
was replaced with an equivalent volume of 0.1% (w v1) trypsin
and 0.02% (w v1) EDTA and the cells were incubated (10 min,
371C). Trypsin (plus cells) was removed and placed in sample-
matched tubes and a second trypsin incubation, followed by gentle
scraping of the polycarbonate filter surface (upper chamber) and
the undersides of each polycarbonate filter as well as the tissue
culture plastic of the lower chambers, ensured that all the cells
were harvested. Cells were centrifuged (200 g, 5 min), the majority
of supernatant removed and tubes reweighed. Cells from each tube
were resuspended in the remaining medium and the cell numbers
counted using a haemocytometer. Noninvading cells were those
remaining in the Transwellt upper chamber and those attached to
the upper surface of the filter. Invading cells were those removed
from the underside of the filter, suspended in the medium of the
tissue culture wells and attached to the base of the 24-well chamber
(cells collected into the lower tubes). A combined analysis of cell
counts plus obtained weight/volume for each cell suspension
(weight of tubes containing cell suspensions minus the weight of
empty tubes) provided a percentage of the total population of cells
that had invaded through fibronectin. (This ‘total housekeeping’
approach to counting all cells is an improvement on the assay first
described by us (Dewhurst et al, 1997)).
Reconstructed skin model of invasion
Full details have been described previously (Chakrabarty et al,
1999; Eves et al, 2000). Briefly, sterile human skin was rehydrated
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in PBS and incubated in 1 M NaCl, which resulted in a de-
epidermised acellular dermis (DED) with retained basement
membrane antigens. Dermal fibroblast cells (1 105) were added
to the reticular DED surface. After 48 h, HBL melanoma cells
(5 104) and epidermal keratinocytes (1 106) were added to
the papillary DED surface. HBL melanoma cells were seeded 4 h
before keratinocytes. After 48 h, the reconstructed skin composites
were raised to an air-medium interface containing a-MSH
(1 109 M)/IBMX (50 mM) or medium alone (control). Compo-
sites were cultured for 2 weeks and the culture medium was
changed every 2–3 days (7a-MSH (1 109 M)/IBMX (50mM)).
External appearance of the upper surface of the composites was
documented by photography prior to fixing in formalin. Paraffin-
fixed histology sections (10 mm) were made for haematoxylin and
eosin staining and for immunolabelling of HMB45 for the
identification of HBL melanoma cells (previously described in
Eves et al, 2000). To assess the extent of invasion, a semiquanti-
tative scoring system of 0– 3 was used. Sections through the centre
of the 1 cm diameter composite were examined for invasion of
HBL cells. In each case, a score of 0 (zero) represented composites
where no melanoma cells were present in the dermis. A score of
0.5 represented 1–5 cells in the dermis, 1.0, 6– 15 cells in the
dermis. A score of 1.5 represented 16–20 cells in the dermis, 2.0,
21–30 cells in the dermis and 2.5, 31– 40 cells in the dermis.
A score of 3.0 was reserved for florid invasion into the dermis
where there were too many cells to count (þ 50 cells).
Statistics
Student’s paired t-test was used to analyse data where identical
cellular treatments were present as a continuous series and where
the only variable involved was the concentration of peptide or drug
used. Nonparametric Mann–Whitney U-test was used to assess
differences in the invasion of melanoma cells in a skin model
containing several variables.
RESULTS
Melanocortin-1 and MC-2 receptor expression
All three melanoma cells were observed to label positively, albeit
weakly, for MC-1R as identified by immunofluorescent microscopy
(Figure 1A). HEK293 cells (which do not express MC-1R) did not
label, as confirmed previously (Moustafa et al, 2002). No
immunoreactivity was observed for cells incubated with isotype
control serum. Western immunoblotting using the same primary
anti-MC-1R antibody revealed a reactive band at 35 kDa molecular
mass for the HBL, A375-SM and C8161 melanoma cell lines (Figure
1B); close to the predicted size of MC-1R, based on sequencing
information (Mountjoy et al, 1992). The extracts of HEK293 cells
did not reveal a similar band. Western blotting using a primary
anti-MC-2R antibody revealed a reactive band at 39 kDa molecular
mass for the HBL and A375-SM cell lines, but not in C8161 cells
(Figure 1B). Higher molecular weight bands were also observed for
both MC-1 and MC-2 receptors, indicating crossreactivity of the
polyclonal sera used.
Melanocortin receptor binding
Receptor saturation studies demonstrated that HBL melanoma
cells (as previously noted) had around 1000–3000 binding sites
per cell and C8161 cells had around 400 receptors per cell (Figure
2A and B). The receptor number for the A375-SM cell line was
much lower and not statistically different to the level of nonspecific
binding achieved (Figure 2). The three cell lines demonstrated
similar binding affinities for a-MSH (summarised in Figure 2B).
However, caution must be used in considering the binding affinity
for the A375-SM due to a relatively low number of receptors
expressed per cell.
Melanocortin-1 receptor sequences
Sequencing of the MC-1R genomic DNA revealed the HBL
melanoma line to be homozygous wild type, the A375-SM line to
contain a homozygous polymorphism for Arg151Cys, while the
C8161 line was heterozygous for Arg151Cys, with the other allele
displaying a wild type sequence.
a-Melanocyte stimulating hormone, cAMP and
intracellular calcium
The human HBL and murine B16F10-C1 melanoma cell line (used
as a positive control) responded to a-MSH concentrations from
1013 to 106 M with increasing cAMP (Figure 3A and B). The
C8161 and A375-SM melanoma cells did not respond to any
concentrations of a-MSH with a detectable level of either
extracellular or intracellular cAMP (Figure 3A and 3B). However,
HBL (Figure 4 (1)), A375-SM (Figure 4 (2)) and C8161 (Figure 4
(3)) melanoma cells all responded with increases in intracellular
Anti-human
    MC-1
 receptor
antobody
 Isotype
 control
antibody
C8161
C8161
A-375SM
A-375SM
HBL
HBL
MC-1R
MC-2R
35 kDa
39 kDa
A
B
Figure 1 (A) Upper micrographs: Presence of MC-1 receptors on HBL,
A375-SM and C8161 melanoma cell lines. Melanocortin-1 receptors (green
fluorescence) were visualised using epifluorescent illumination (FITC filter,
lex¼ 490 nm, lem¼ 523 nm) and nuclei (red fluorescence) were visualised
with a rhodamine filter (lex¼ 555 nm, lem¼ 580 nm). Lower micrographs:
Corresponding cell lines using isotype control primary antibody demon-
strating observed specificity of immunolabelling. Bar¼ 20mm. (B) Western
blotting of HBL, A375-SM and C8161 melanoma cell lines for MC-1 and
MC-2 receptors.
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calcium to a-MSHþ PIA addition at concentrations of a-MSH
from 1013 M to 106 M. Increases in intracellular calcium were
only ever observed in the presence of 10 mM PIA (a pharmacolo-
gical adenosine agonist that inhibits any elevation of cAMP).
(þ ()-N6-(2-phenylisopropyl)-adenosine alone did not elevate
calcium in any of the cell lines (results not shown). It was observed
that the magnitude of the response obtained for the C8161
melanoma line (Figure 4 (3)) was consistently greater than that
observed for the HBL or A375-SM lines (Figure 4 (1 or 2)). A
summary of intracellular calcium responses is given in Table 1.
a-Melanocyte-simulating hormone and the invasion of
melanoma cells through human fibronectin
As the three melanoma cell lines invaded through the fibronectin-
Transwellt layer at different rates, the invasion assay incubation
time was adjusted to obtain a reproducible number of cells
invading under basal control conditions, equivalent to between 20
and 50% of total cell number. The C8161 melanoma cell line was
highly invasive with 4976.8% of the total cell population invading
after 15 h (n¼ 5). In contrast, the HBL melanoma cell line gave
invasion of 4272% (n¼ 10) after 20 h and A375-SM cells were the
least invasive with 2072.6% of the total cell population invading
after 52 h (n¼ 7).
Using the above experimental conditions, a-MSH significantly
inhibited invasion of the HBL melanoma cells through fibronectin
(results are presented as the mean percentage of invasion found in
the control), in a concentration-dependent manner (Figure 5A). A
maximum inhibition of 58% for HBL cells was observed using
107 M a-MSH. For A375-SM melanoma cells, relatively low
concentrations of a-MSH (1012 –1010 M) were observed to
significantly inhibit invasion with 1012 M, demonstrating 46%
inhibition (Figure 5B). Interestingly, a-MSH concentrations above
109 M were ineffective in inhibiting invasion of this cell line. In
contrast, a-MSH had no effect on the invasive ability of C8161 cells
through human fibronectin (Figure 5C). However, when these cells
were stably transfected with the wild-type MC-1R, a-MSH (at
107 M) inhibited invasion by approximately 30% (7271.9%,
n¼ 4, Po0.0006, Figure 5D). With the HBL melanoma cells, the
inhibitory effect of a-MSH was confirmed to be via a cAMP
mechanism by using the receptor-independent agents, IBMX and
forskolin. Table 2 shows that IBMX (at 5 104 M) significantly
inhibited HBL melanoma cell invasion by 70% and forskolin (at
1 104 M) inhibited invasion by 59%. For A375-SM cells, the
largest inhibition of invasion observed was with 1 104 M IBMX
(36%) or 1 105 M forskolin (39%), but neither results were
statistically significant. A cAMP mechanism was also confirmed
for the C8161 melanoma cell line, as cell invasion was inhibited by
1 105 M (21%) and 1 106 M (53%) forskolin. Furthermore,
combination of a-MSH (1 109 M) and IBMX (5 105 and
1 104 M) with HBL melanoma cells resulted in a further
significant reduction in HBL invasion, compared to either a-
MSH or IBMX alone (Table 3). However, no further reduction in
B
A
B 
/ B
o 
(%
)
0
25
50
75
100
Log NDP-MSH molarity
−6−7−8−9−10−11−12−13
Log NDP-MSH molarity
−6−7−8−9−10−11−12−13
Sp
cc
ific
 b
in
id
in
g 
(c.
p.m
.)
0
500
1000
1500
2000
2500
3000
3500
Figure 2 (A) Competitive binding of a-MSH for radiolabelled
Nle4DPhe7-MSH was performed to saturation showing displacement data
for HBL, A375-SM and C8161 melanoma cells, allowing calculation of total
receptor numbers. (B) Competitive binding data was used to determine
the affinity of melanoma cells for a-MSH (circles, HBL; squares, C8161;
triangles, A375-SM; means7s.e.m., n¼ 3).
300
800
700
600
500
400
300
200
100
200
100
0
Ex
tra
ce
llu
la
r c
yc
lic
 A
M
P 
(pm
ol 
ml
−
1 )
0 −13 −12 −11 −10 −9 −8 −7 −6
-MSH (M)
-MSH (M)
0
In
tra
ce
llu
la
r c
yc
lic
 A
M
P 
(%
 co
ntr
ol)
0 −12 −11 −10 −9 −8 −7 −6
A
B
Figure 3 Detection of extracellular (A) and intracellular (B) cAMP in
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invasion was observed when forskolin (1 104 M) was combined
with a-MSH (1 109 M), in comparison to either agent alone.
a-Melanocyte-simulating hormone and melanoma cell
invasion through reconstructed skin
A more clinically relevant model of human reconstructed skin
(detailed in Eves et al, 2000) was used to investigate the actions of
a-MSH on invasion of the HBL melanoma cell line. The other two
cell lines were not investigated using this model, as they had shown
limited (A375SM) or no (C8161) response to a-MSH in the
fibronectin invasion model. A midrange inhibitory concentration
of 1 109 M a-MSH was used. In order to potentiate a-MSH in
this model, it was also combined with 5 105 M IBMX. Addition
of a-MSH/IBMX had no obvious effect on the pigmentation of the
HBL cells (Figure 6A–C) in this skin model and did not affect the
gross morphology of the composites; however, it did affect HBL
dendricity (results not shown).
After a 2-week culture period where the composites were
routinely fed with fresh media containing a-MSH (1 109 M) and
IBMX (5 105 M) every 3–4 days, they were sectioned and
immunohistochemically labelled with an antibody to HMB45.
Visual analysis of these sections clearly demonstrated that
compared to control composites (Figure 7A, C, E), a-MSH/IBMX
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Figure 4 Intracellular calcium responses of (1) HBL (2) A375-SM
and (3) C8161 melanoma cells to a-MSHþ PIA (10 mM). Cells were
loaded with Fura-2 AM and the intracellular calcium release was detected
by optical fluorimetry. þ ()-N6-(2-phenylisopropyl)-adenosine was always
added at the same time as a-MSH indicated by position of indivi-
dual vertical arrows. (a) a-MSH (1011 M); (b) a-MSH (109 M) and
(c) a-MSH (107 M).
Table 1 Summary of the number of observed positive responses to a-
MSH+PIA (10 mM) in inducing an intracellular calcium signal in HBL, A375-
SM and C8161 melanoma cells
a-MSH (M)+PIA
(10 lM)
Number of coverslips responding with an
increase in calcium
HBL A375-SM C8161
1013 M 3/6 6/6 2/2
1012 M 5/6 6/6 1/1
1011 M 9/9 7/7 4/4
1010 M 6/6 6/6 3/3
109 M 6/6 6/6 5/5
108 M 6/6 6/6 5/5
107 M 6/6 7/7 4/4
106 M 6/6 10/10 6/6
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Figure 5 Effect of a-MSH on melanoma invasion through human
fibronectin. The invasion assay was run for (A) 20 h with HBL melanoma
cells, (B) 52 h with A375-SM cells, (C) 15 h with C8161 cells and (D) 15 h
with untransfected and stably transfected (with MC-1R) C8161 cells. Values
shown represent the raw data (% mean invasion) obtained for each
experiment, which were normalised by relating all values to the control
level of invasion in each individual experiment (taken as 100%). Statistical
comparison is made between invasion in the absence (control) and
presence of a-MSH. *Po0.05, **Po0.01, ***Po0.001.
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(Figure 7 B, D, F) had inhibited HBL invasion into the dermis.
Semiquantitative analysis (see Figure 6D) was used to assess the
extent of HBL invasion in the presence and absence of a-MSH/
IBMX. Extensive invasion in the absence of a-MSH/IBMX was
observed in 22 out of 23 composites, while invasion in the presence
of a-MSH/IBMX was only observed in 15 out of 25 composites. The
overall inhibition was 59% (Po0.0005).
a-Melanocyte-simulating hormone and cytokine-induced
activation of NFjB/p65 in melanoma cells
NF-kB translocation from the cytoplasm into the nucleus was
observed for all melanoma lines (HBL, A375-SM, C8161) in
response to stimulation with TNF-a (60 min; shown for A375-SM,
Figure 8). Control untreated melanoma cells showed no evidence
of NF-kB activity (Figure 8A). After 1-h incubation with TNF-a
(300 U ml1), 85% of A375-SM cells showed an increase in
activation (Figures 8B and 9B). Addition of a-MSH alone
(1012 –108 M) had no effect (Figure 8C and 9B); however; a
15 min preincubation (1012 – 108 M) followed by a 1 h stimulation
with TNF-a (300 U ml1) resulted in a significant, concentration-
dependent inhibition of TNF-a-induced NFkB/p65 activation
(Figures 8D and 9B). HBL cells displayed 97% NF-kB activation
in response to TNF-a. Addition of a-MSH alone (109106 M) had
no effect, but preincubation with a-MSH (109 – 106 M) for 15 min
followed by a 1 h stimulation with TNF-a (300 U ml1) resulted in a
concentration-dependent inhibition of TNF-a stimulated activity
(Figure 9A). C8161 cells also had inactive NF-kB in the absence of
stimulators. Treatment with TNF-a (300 U ml1) for 1 h activated
NF-kB to 88% of cells (Figure 9C). Addition of a-MSH alone
(109 M to 106 M) resulted in a very slight but not significant
increase in NF-kB activity (Figure 9C). Preincubation of the C8161
cell line with a-MSH (1 109 –1 106 M) followed by a 1 h
stimulation with TNF-a (300 U ml1) only inhibited NFkB/p65
activation by around 10 –15%. This was demonstrated to be
marginally significant (Po0.05), but compares poorly to the 70%
inhibition of a-MSH on HBL cells, and 35% inhibition on A375-SM
cells.
DISCUSSION
The aim of this study was to find out more about the role of a-MSH
in influencing melanoma progression. We compared three
genetically distinct human melanoma cell lines and examined to
what extent a-MSH influenced cell invasion through a fibronectin
protein layer and (for one of the lines) through a reconstructed
skin model. The results obtained were compared with the ability of
a-MSH to inhibit proinflammatory cytokine TNF-a activation of
NF-kB, elevate cAMP and stimulate intracellular calcium. The
main findings of this study were that while all three lines expressed
MC-1R, they differed markedly in their response to a-MSH. For
HBL cells, which express wild-type MC1R, a-MSH elevated
intracellular and extracellular cAMP, induced an increase in
intracellular calcium, was very effective at inhibiting invasion of
cells through fibronectin and through a reconstructed skin model
and also attenuated the response of the cells to TNF-a. The A375-
SM cells were homozygous for Arg151Cys for the MC-1R, and
responded partially in that a-MSH inhibited invasion and the
response to TNF-a at low a-MSH concentrations, but with
negligible responses at higher concentrations. a-Melanocyte-
simulating hormone induced intracellular calcium levels but did
not elevate intracellular or extracellular cAMP to detectable levels.
C8161 cells were heterozygous Arg151Cys for MC-1R, and were
unresponsive to a-MSH with inhibiting invasion, had a small
inhibitory response to TNF-a and failed to elevate intracellular or
extracellular cAMP (although intracellular calcium responses were
detected). However, stable transfection of these cells with the wild-
type MC-1R showed that these cells were then able to respond to a-
MSH with a significant reduction in invasion.
Table 2 Summary of the effect of a-MSH, IBMX, forskolin on the invasion of melanoma cells through human fibronectin
% Control invasion (mean+s.e.m. (n))
Agent Concentration (M) HBL A375SM C8161
Control — 10074.8 (10) 100713 (7) 100713.9 (5)
a-MSH 1 1012 — 5473.6 (5)* —
1 1011 110719.1 (3) 7779.7 (7)*** 9471.5 (3)
1 1010 86712.1 (4) 84710.8 (7)* 10179 (3)
1 109 6572.3 (13)*** 9978.3 (6) 10175.5 (3)
1 108 4472.5 (3)* 109715.2 (6) 9878.1 (3)
1 107 4277.9 (3)* — 100714.3 (3)
IBMX 1 105 9877.5 (3) — —
5 105 7377.1 (7)* 10876.9 (3) —
1 104 5574 (7)*** 64713.1 (3) —
2.5 104 45711.7 (3) 7779.7 (3) —
5 105 3075.8 (3)* — —
Forskolin 1 106 11376.8 (3) — 10976 (3)
1 105 102710 (6) 61710.1 (3) 7975 (3)*
1 104 4173.2 (6)*** 10972.8 (3) 4776 (3)**
Statistical comparison is made between invasion in the absence (control) and presence of pharmacological agent. *Po0.05, **Po0.01, ***Po0.001.
Table 3 Summary of the effect of a-MSH, IBMX, forskolin and H89 on
the invasion of HBL melanoma cells through human fibronectin
Agent(s)
% Control invasion of HBL cells
(mean7s.e.m. (n))
Control 10074.8 (13)
a-MSH (10 – 9 M) 6572.3 (13)***
IBMX (5 105 M) 7377.1 (7)*
IBMX (104 M) 5574 (7)***
a-MSH (109 M)+IBMX (5 105 M) 4877.4 (3)*
a-MSH (109 M)+IBMX (104 M) 3575.9 (4)***
Forskolin (105 M) 102710 (6)
Forskolin (104 M) 4173.2 (6)***
a-MSH (109 M)+forskolin (105 M) 101715.9 (3)
a-MSH (109 M)+forskolin (104 M) 3972.2 (3)**
Statistical comparison is made between invasion in the absence (control) and
presence of pharmacological agent. *Po0.05, **Po0.01, ***Po0.001
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The HBL melanoma cell line has previously been demonstrated
to express 1000–3000 MSH receptor-binding sites per cell
(Ghanem et al, 1988), and A375 and C8161 melanoma cell lines
have also been demonstrated to have MSH receptors (Baumann
et al, 1997) and MSH binding sites (Sharma et al, 1996). In
comparison, normal human cutaneous melanocytes are reported
to express between 300 and 1000 binding sites per cell (Donatien
et al, 1992; De Luca et al, 1993). In the present study, MC-1
receptors were identified on the cells by immunofluorescent
microscopy, Western blotting and MSH binding sites using
radiolabelled a-MSH. In addition, we also sequenced both alleles
of the MC-1 receptor genomic DNA. Western blotting identified
the presence of the MC-1 receptor at a molecular weight of 35 kDa,
corresponding to the predicted molecular weight based on DNA
sequencing data. As previously reported, binding studies con-
firmed that HBL melanoma cells had a relatively high receptor
number. C8161 cells had a number approximating that found in
normal skin melanocytes, while A375-SM cells had a relatively low
number of receptors. However, all cells displayed similar receptor
binding affinity for a-MSH. (It was interesting to note that the HBL
and A375-SM cell lines were also positive for the MC-2R, in
contrast to the C8161 melanoma line.) Melanocortin-1 receptor
DNA sequencing showed that the HBL line expressed wild-type
MC-1R, whereas the A375-SM and C8161 lines were homozygous
and heterozygous for Arg151Cys, respectively. This polymorphism
is known to convey a loss of function on receptor coupling to
cAMP (reviewed in Wikberg et al, 2000). The heterozygous
expression of Arg151Cys would suggest a potential for signalling;
however, partially functional responses in the A375-SM line
(homozygous Arg151Cys) would suggest either that this poly-
morphism conveys some function (as opposed to total loss) or that
a signal other than cAMP is conveyed from the receptor in a region
outside of the Arg151Cys site.
A number of polymorphic studies of the MC receptor are related
to incidence of melanoma (Box et al, 1997; Jime´nez-Cervantes et al,
2001). However, not all studies are in agreement (Ichii-Jones et al,
1998). a-Melanocyte-simulating hormone has been demonstrated
to affect melanoma growth and attachment to ECM proteins in
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Figure 6 Melanoma cell invasion through reconstructed skin. Morphol-
ogy (A–C) of composites and the extent of HBL invasion (D) through
reconstructed skin7a-MSH/IBMX. In (A) composites contain keratino-
cytes (K) and fibroblast (F) cells; in (B) composites contain keratinocytes,
fibroblasts and HBL melanoma cells, and in (C) composites contain
keratinocytes, fibroblasts, HBL melanoma cells and a-MSH/IBMX. Statistical
comparison in (D) is made between HBL cell invasion in the absence
(control) and presence of a-MSH/IBMX. ***Po0.001.
Figure 7 Histology of melanoma invasion through reconstructed skin
composites containing keratinocytes, fibroblasts and HBL cells7a-MSH/
IBMX. Composites were cultured for 14 days in the absence (A, C and E)
and presence (B, D and F) of a-MSH (1 109 M)/IBMX (50 mM).
Composites have been labelled for HMB45 (for detection of HBL cells). Bar
for (A)– (F)¼ 40mm; bar for (E)¼ 20 mm.
a-MSH inhibits human melanoma cell invasion
P Eves et al
2011
British Journal of Cancer (2003) 89(10), 2004 – 2015& 2003 Cancer Research UK
E
x
p
e
ri
m
e
n
ta
l
T
h
e
ra
p
e
u
ti
c
s
cells with wild-type MC-1, but not in cells transfected with
polymorphic variants (Robinson and Healy, 2002). The current
study provides strong evidence to suggest that two out of three
human cell lines that possessed MC-1R polymorphisms, which
gave a loss of cAMP response to MSH, resulted in cells that failed
to respond to MSH with any reduction of invasion or protection
against proinflammatory cytokine attack. Stable transfection of the
C8161 cell line with the wild-type MC-1R and introduction of
sensitivity to a-MSH provides possibly the strongest evidence yet
that this receptor is involved in melanoma invasiveness.
As previously stated, there is controversy concerning the role a-
MSH in the progression of melanoma. Most of the experimental
studies have been carried out on murine melanoma cell lines,
known to express between 3000 and 10 000 MSH binding sites per
cell (Lambert and Lerner, 1983; Siegrist et al, 1989; Lunec et al,
1993), while human melanoma cells only express around 1000–
3000 binding sites per cell (Ghanem et al, 1988). It is difficult to
make firm conclusions concerning the role of a-MSH in human
melanoma progression from murine studies. The inhibitory effect
of a-MSH on the HBL cell line is similar to that reported previously
(Murata et al, 1997) for highly invasive murine B16-BL6 melanoma
cells. Melanoma invasion of the three cell lines was also inhibited
(achieving significance for two out of three cell lines) by forskolin
and/or IBMX (agents which elevate cAMP), supporting the idea
that melanoma invasion is under the influence of adenylate
cyclase/cAMP post-receptor signalling. This is consistent with
earlier investigations showing a positive correlation between cAMP
responsiveness of murine melanoma cell lines in vitro and the
metastatic success of these lines in vivo (Sheppard et al, 1986; Hill
et al, 1990).
The use of a reconstructed human skin model is particularly
useful for studying melanoma cell invasion, as it provides a
physiologically relevant dermal and epidermal structure (Eves et al,
2000). The melanoma cells are physically proximal to human
keratinocytes and fibroblasts contained within an architecture that
very closely approximates that of native skin tissue. The
model also has a basement membrane structure, which is highly
relevant to melanoma metastasis. Using this model we found that
a-MSH (at 109 M)/IBMX (5 105 M) inhibited HBL melanoma
cell invasion by 59%.
a-Melanocyte-simulating hormone can inhibit TNF-a-stimu-
lated NF-kB activity in human melanocytes, melanoma cells and
keratinocytes (Haycock et al, 1999, 2000; Moustafa et al, 2002). In
all of these cells, a-MSH inhibited the response to TNF-a by
around 50%. In the current study, TNF-a activated NFkB/p65 in
over 80% of all melanoma cells within 60 min. The HBL melanoma
line responded to a-MSH with an inhibition of NF-kB. The A375-
SM melanoma line responded to low a-MSH concentrations with
an inhibition of NF-kB, whereas higher a-MSH concentrations
were ineffective. In contrast, C8161 cells were largely unresponsive
to any a-MSH concentrations.
The correlation observed between the anti-invasive response of
the melanoma lines and the anti-inflammatory response to a-MSH
was very strong. We have shown previously that the anti-
Figure 8 A375-SM melanoma cells immunolabelled for the p65 subunit
of the NF-kB complex. The p65 subunit (green fluorescence) was
visualised using epifluorescent illumination (FITC filter, lex¼ 490 nm,
lem¼ 523 nm), while nuclei (red fluorescence) were visualised with a
rhodamine filter (lex¼ 555 nm, lem¼ 580 nm). Cells were either left
untreated (A), stimulated with TNF-a (300 U ml1, 60 min) (B), treated
with a-MSH (109 M) (C) alone, or pretreated with a-MSH (109 M,
15 min) followed by stimulation with TNF-a (300 U ml1, 60 min) (D).
Activation of NF-kB is observed as translocation to the nucleus (TNF-a
alone, B) and inhibition by a-MSHþTNF-a as retention in the cytoplasm
(D). Bar¼ 100 mm.
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Figure 9 Effect of a-MSH on TNF-a stimulated NF-kB activity in (A)
HBL, (B) A375-SM and (C) C8161 melanoma cells. Statistical comparison
is made between cells treated with TNF-a alone and cells pretreated with
a-MSH followed by stimulation with TNF-a. *Po0.05, **Po0.01,
***Po0.001.
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inflammatory response to a-MSH is also mediated via cAMP,
suggesting a strong correlation between anti-invasive and anti-
inflammatory responses. HBL melanoma cells responded to a-
MSH in a concentration-dependant manner with elevation in
intracellular and extracellular cAMP (as did the murine B16 F10C1
melanoma line, used as a positive control). However, the A375-SM
and C8161 lines had no detectable increases in cAMP. The lack of
an a-MSH response observed for the C8161 cells and a partial
response for the A375-SM cells are consistent with the lack of a
cAMP signal in these cells.
In contrast, all cell lines responded to a-MSH with acute
elevations in intracellular calcium. Dual signalling from the MC
receptor is not a new concept. In 1984, a-MSH-stimulated
adenylate cyclase was reported to be regulated by calcium and
calmodulin in a biphasic manner. Submicromolar concentrations
of calcium were shown to be required for optimal a-MSH-
stimulated cAMP production; slightly higher micromolar concen-
trations led to inhibition of adenylate cyclase (Mac Neil et al, 1984)
and activation of calcium/calmodulin phosphodiesterase, resulting
in cAMP breakdown in murine melanoma cells. In these same
cells, a-MSH was also demonstrated to activate protein kinase C
(Buffey et al, 1992). Although a-MSH may activate the phospho-
lipase C signalling pathway (resulting in increased inositol
phosphates, intracellular calcium and activation of protein kinase
C) in addition to activating the adenylate cyclase cAMP signalling
pathway, the overwhelming evidence from the literature (as
reviewed in Eberle, 1988) points to the majority of the actions of
a-MSH being mediated by cAMP. The relevance of the dual
signalling remains unclear although the calcium signal can modify
the cAMP-mediated actions of a-MSH on melanogenesis (Buffey
et al, 1992). The simplest hypothesis to explain dual signalling is
that most actions of the a-MSH-induced phospholipase C
signalling are explained by it suppressing the a-MSH-induced
cAMP signal (as proposed in Mac Neil et al, 1984). There is
nothing in the current study to contradict this hypothesis as all of
the functional biology of a-MSH that we observed could be
mimicked by elevating cAMP. The two cell lines that failed to
generate a cAMP signal to a-MSH did give a calcium signal,
indicating that the receptors were adequately coupled to generate
calcium but not cAMP.
The data obtained in this study highlight an interesting question
regarding MC receptor expression and the functional activity of a-
MSH in melanoma cells. While immunofluorescent microscopy
demonstrated that all three melanoma lines express MC-1
receptors, a-MSH binding studies showed that only HBL cells
have a high number of MSH receptors capable of generating a
cAMP signal. Melanocortin-1 receptor polymorphisms have been
associated with red hair and fair skin, and also with cutaneous
melanoma in humans. Hence, it is of considerable interest that two
of the lines investigated in this study contained homozygous and
heterozygous polymorphisms, respectively. The Arg151Cys poly-
morphism, along with others (Arg160Trp and Arg294His) results
in loss of receptor function, with association of an increased risk
for melanoma (reviewed in Xia et al, 1995). The importance of
receptor polymorphisms is further highlighted by the fact that
when C8161 cells were stably transfected with the wild-type MC-
1R, the cells then responded with a significant inhibition of
invasion in response to a-MSH.
Melanoma cells that possess sufficient functional MC receptors
may therefore respond to endogenous or exogenous a-MSH with a
reduction in their ability to invade through ECM proteins, and
ability to resist proinflammatory cytokines. The former properties
would tend to reduce melanoma invasion. Equally, it might be
argued that resisting proinflammatory cytokine action is consis-
tent with promoting melanoma invasion by assisting melanoma
cells to escape immune surveillance. It is difficult to conclude how
important the anti-invasive actions of a-MSH in vitro are vs the
protective (and hence proinvasive) activity in preventing immune
detection. We speculate that a-MSH may retard melanoma escape
from the primary tumour on the one hand (and initial metastasis),
and on the other may promote melanoma invasion by reducing the
response of cells to proinflammatory cytokines. Thus, a simple
hypothesis to explain our present data would be that a-MSH
initially acts to reduce early tumour spread, but affords protection
to those cells that do escape from a primary tumour site.
A major biological function of a-MSH in the melanocyte,
probably retained in the melanoma cell, may be the protection of
cells from proinflammatory cytokines and oxidative stress. A
common response of cells to such stress includes upregulation of
adhesion molecules, some of which would normally bring cells to
the attention of the immune system. Adhesion molecules such as
integrins may also be upregulated and promote melanoma
interaction with ECM proteins in terms of migration and invasion
through the ECM. We have recently shown that while the
proinflammatory cytokine TNF-a upregulates integrin (a3, a4,
b1) expression in HBL melanoma cells, treatment with a-MSH
results in a reduction in integrin expression (Zhu et al, 2002).
These results suggest that a-MSH can effectively reduce cytokine-
induced upregulation of adhesion molecules such as integrins that
would tend to increase melanoma invasiveness through ECM
proteins while also reducing expression of adhesion molecules that
promote interaction between melanoma cells and the immune
system (e.g. ICAM-1 as we previously demonstrated (Hedley et al,
1998b; Morandini et al, 1998)), thus enhancing melanoma escape
of immune surveillance.
In conclusion, this study suggests that a-MSH has the potential
to retard metastatic spread but also to reduce the ability of the
immune system to detect tumour cells, in some melanoma cells.
Both responses to a-MSH appear to be linked to the cAMP
signalling pathway, but clearly the downstream signalling from the
MC-1R is complex and far from resolved. As metastatic melanoma
remains an extremely challenging cancer to treat, we suggest the
role of a-MSH in melanoma progression merits further investiga-
tion as it may hold clues to the metastatic success of the tumour
and may offer new approaches to developing therapies to reduce
metastatic spread or enhance the ability of these cells to be
detected by the immune system.
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